Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Does Nano-Curcumin Supplementation Improve Hematological Indices in Critically Ill Patients With Sepsis? a Randomized Controlled Clinical Trial Publisher Pubmed



Naeini F1 ; Tutunchi H2, 3 ; Razmi H4 ; Mahmoodpoor A5 ; Vajdi M6 ; Sefidmooye Azar P7 ; Najifipour F3 ; Tarighatesfanjani A2 ; Karimi A2, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Science, Tehran, Iran
  2. 2. Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
  3. 3. Endoceine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
  4. 4. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  5. 5. Department of Anatomical Sciences, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
  6. 6. Student Research Committee, Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran
  7. 7. Department of Nutrition and Hospitality Management, School of Applied Sciences, The University of Mississippi, University Park, MS, United States

Source: Journal of Food Biochemistry Published:2022


Abstract

Sepsis is the final common pathway to death for severe infectious diseases worldwide. The present trial aimed to investigate the effects of nano-curcumin supplementation on hematological indices in critically ill patients with sepsis. Fourteen ICU-admitted patients were randomly allocated into either nano-curcumin or placebo group for 10 days. The blood indices, serum levels of inflammatory biomarker and presepsin as well as nutrition status, and clinical outcomes were assessed before the intervention and on days 5 and 10. White blood cells, neutrophils, platelets, erythrocyte sedimentation rate (ESR), and the levels of interleukin-8 significantly decreased in the nano-curcumin group compared to the placebo after 10 days of intervention (p =.024, p =.045, p =.017, p =.041, and p =.004, respectively). There was also a marginal meaningful decrease in serum presepsin levels in the intervention group compared to the placebo at the end of the study (p =.054). However, total lymphocyte count showed a significant increase in the nano-curcumin group compared to the placebo at the end-point (p =.04). No significant differences were found in the level of lymphocyte and the ratios of neutrophil/lymphocyte and platelet/lymphocyte between the study groups. Moreover, no significant between-group differences were observed for other study outcomes, post-intervention. Collectively, nano-curcumin may be a useful adjuvant therapy in critically ill patients with sepsis. However, further trials are suggested to examine the effects of nano-curcumin in the management of sepsis and its complications. Practical applications: Curcumin (1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5- dione) or diferuloylmethane is widely used in medicine due to its several biological properties. Recent evidence has shown that curcumin possesses multiple pharmacological activities including immune-modulatory, antioxidant, anti-inflammatory, anti-cancer, and anti-microbial effects. In this study, it was observed that nano-curcumin at a dose of 160 mg for 10 days, without side effects, reduced some inflammatory factors and regulated the immune responses in sepsis patients. For the first time, this trial was conducted to determine the effect of nano-curcumin on hematological indices and the serum levels of presepsin and IL-8. © 2022 Wiley Periodicals LLC.
Experts (# of related papers)